Today techs Ultimovacs Proclaims Plenary Oral Presentation of Part I

today techs

  • New medical information from part I trial UV1-103, combining UV1 with pembrolizumab in superior melanoma shall be introduced

Oslo, September 21 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a medical stage chief in immune stimulatory vaccines for most cancers, introduced immediately that additional information from its medical research on the mix of its common most cancers vaccine, UV1, and the PD-1 checkpoint inhibitor, pembrolizumab, shall be disclosed in an oral presentation on the 19th Worldwide Congress of the Society for Melanoma Analysis (SMR) on 18 October 2022.

The presenter shall be Dr. Yousef Zakharia, Investigator for the UV1-103 medical trial. Dr. Zakharia is a Medical Oncologist, Medical Affiliate Professor and Director Part I Program at College of Iowa Hospital and Clinics.

“I’m happy to current the outcomes from the UV1-103 trial to worldwide friends in today techs melanoma analysis”, mentioned Dr. Yousef Zakharia. Carlos de Sousa, CEO of Ultimovacs added: “As Ultimovacs’ 5 randomized part II trials of UV1 proceed to mature, there’s rising curiosity within the capacity of the vaccine to induce long-lasting, survival-associated immune responses. We’re honored to have the ability to current additional information on the medical exercise of UV1.”

Ultimovacs’ presentation is entitled ‘Medical Exercise of Mixed Telomerase Vaccination and Pembrolizumab in Unresectable Melanoma’ and shall be given as an oral presentation on the Worldwide Congress of the Society for Melanoma Analysis. Society for Melanoma Analysis shall be on-line and in-person in Edinburgh, UK, October 17 – 20, 2022. The congress brings collectively the leaders within the subject of fundamental and today techs translational melanoma analysis and melanoma medical trial physicians from around the globe.

The presentation shall be made obtainable on the Firm web site on October 18, 2022.

***

About the UV1-103 part I trial in Malignant Melanoma
This US-based Part I medical trial is evaluating the Firm’s lead candidate, UV1, together with PD-1 checkpoint inhibitor, pembrolizumab, as a first-line remedy in sufferers with metastatic malignant melanoma. The medical outcomes for today techs the 30 sufferers enrolled today techs are:

  • Goal response charge (ORR): 57%, full response charge (CR): 33%
  • Median Development Free Survival (mPFS): 18.9 months (as measured by iRECIST)
  • General survival after 12 months: 87%, general survival after 24 months: 73%

Sufferers will proceed to be adopted for long-term survival. UV1 has demonstrated a superb security profile, and no sudden issues of safety associated to UV1 have been noticed on this trial.

The U.S. Meals and Drug Administration (FDA) granted a twin Quick Observe designation for UV1 together with checkpoint inhibitors within the remedy of unresectable or metastatic melanoma both as add-on remedy to pembrolizumab or as add-on remedy to ipilimumab. Ultimovacs is presently evaluating UV1 as add-on remedy to ipilimumab and nivolumab as first-line remedy for unresectable or metastatic melanoma in a Part II research named INITIUM.

About Ultimovacs 
Ultimovacs is an immunotherapy firm creating immune-stimulatory vaccines to deal with a broad vary of cancers. Ultimovacs’ lead common most cancers vaccine candidate UV1 targets human telomerase (hTERT), current in 85-90% of cancers in all levels of tumor development. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T today techs cells to the tumor to activate an immune system cascade and improve anti-tumor responses. With a broad Part II program in 5 most cancers indications enrolling greater than 650 sufferers, Ultimovacs goals to clinically exhibit UV1’s impression in a number of most cancers varieties, together with different immunotherapies, for sufferers with unmet wants. Ultimovacs’ second expertise method, primarily based on the proprietary Tetanus-Epitope-Focusing on (TET) platform, combines tumor-specific peptides and adjuvant in the identical molecule and entered Part I research in 2021. 

For additional info, please see www.ultimovacs.com or contact: 

Carlos de Sousa, CEO  
E mail: carlos.desousa@ultimovacs.com
Telephone: +47 908 92507  

Anne Worsøe, Head of Investor Relations
E mail: ir@ultimovacs.com
Telephone: +47 906 86 815

Mary-Ann Chang, LifeSci Advisors 
E mail: mchang@lifesciadvisors.com 
Telephone: +44 7483 284 853 

 

today techs
today techs

Be the first to comment

Leave a Reply

Your email address will not be published.


*